Pulvirenti L, Kastin A J
VA Medical Center, New Orleans, LA 70146.
Eur J Pharmacol. 1988 Jul 7;151(2):289-92. doi: 10.1016/0014-2999(88)90810-2.
Previous studies have shown effects of MIF-1 (prolyl-leucyl-glycinamide) and Tyr-MIF-1 (tyrosyl-prolyl-leucyl-glycinamide) in animal models of depression and also effects on dopaminergic function. These observations prompted us to examine whether the effects of the two peptides in the behavioral 'despair' test were modulated by dopamine antagonists. MIF-1 and Tyr-MIF-1, at the small dose of 0.01 mg/kg i.p. (24, 5 and 1 h before the test), produced a significant anti-immobility effect. This effect was antagonized by a single injection of either haloperidol or sulpiride, two dopamine receptor blockers. The same low dose of the tricyclic antidepressant desipramine was without significant effect in this test. The results indicate that Tyr-MIF-1, like MIF-1, is active in the behavioral despair test for antidepressants and that at least some of the CNS actions of these peptides are mediated by dopamine receptors.
先前的研究已表明,MIF-1(脯氨酰-亮氨酰-甘氨酰胺)和Tyr-MIF-1(酪氨酰-脯氨酰-亮氨酰-甘氨酰胺)在抑郁症动物模型中具有作用,并且对多巴胺能功能也有影响。这些观察结果促使我们研究在行为“绝望”试验中这两种肽的作用是否受到多巴胺拮抗剂的调节。在腹腔注射小剂量0.01 mg/kg的MIF-1和Tyr-MIF-1(在试验前24、5和1小时)时,产生了显著的抗不动效应。单次注射两种多巴胺受体阻滞剂氟哌啶醇或舒必利可拮抗这种效应。相同低剂量的三环类抗抑郁药地昔帕明在该试验中无显著作用。结果表明,Tyr-MIF-1与MIF-1一样,在抗抑郁药的行为绝望试验中具有活性,并且这些肽的至少一些中枢神经系统作用是由多巴胺受体介导的。